Hypofractionation for Regional Nodal Irradiation: Standard of Care or Investigational Only?

This activity will begin with a review of the data for hypofractionation of regional nodal irradiation (RNI). That review will cover patients with intact breasts, post-mastectomy without reconstruction and post-mastectomy with reconstruction. It will include published data, as well as ongoing trials (including timeline for reporting of ongoing trials such as RT CHARM). It will also include the data on moderate hypofractionation and 5-fraction hypofractionation (such as UK data that was just presented at ESTRO, not yet published). Following the data review, two experts in the field will debate whether or not they use hypofractionation for RNI which will involve how they apply and interpret the data. The expert who is "pro" hypofractionation for RNI will also review the specific dose fractionation, dose constraints and patient setup considerations that are relevant.

Topics:

  1. Hypofractionation and Regional Nodal Irradiation: State of the Evidence
    Matthew M. Poppe, MD
  2. Hypofractionation for Regional Nodal Irradiation should be the Standard of Care
    Anna Kirby, MD
  3. Hypofractionation for Regional Nodal Irradiation: Investigational Only
    Julia R. White, MD, FASTRO
  4. Q and A

This activity is available from November 28, 2023, through 11:59 p.m. Eastern time on November 27, 2025. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, and residents. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Better understand the existing data for hypofractionation for regional nodal irradiation. 
  • Better understand how experts in the field interpret and apply this data to support their practice.  
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
11/28/2023
Course expires: 
11/27/2025
Cost:
$0.00
Rating: 
0
  • Naamit Kurshan Gerber, MD, is employed by Department of Radiation Oncology, NYU Langone Health. Dr. Gerber receives research funding from PreludeDx. Dr. Gerber receives honoraria from Mount Sinai Icahn School of Medicine and John Theurer Cancer Center. Dr. Gerber is a member of the ASTRO APBI Guidelines Committee and serves as Chair of a Key Question Committee.  
  • Matthew M. Poppe, MD, is employed by Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah. Dr. Poppe receives honoraria from Mevion. Dr. Poppe serves as Vice Chair of the Breast Committee with the Alliance for Clinical Trials in Oncology and is a member of the NCI BOLD task force of the breast committee. 
  • Julia R. White, MD, FASTRO, is employed by the University of Kansas Medical Center. Dr. White serves in an uncompensated role with the National Coalition of Breast Centers (NCBI). She also serves as Vice Chair of the NCI National Clinical Trials Network with NRG Oncology.   
  • Anna Kirby, MD, is employed by Institute of Cancer Research/Royal Marsden NHS Foundation Trust. Dr. Kirby serves as President for the European Society of Radiotherapy and Oncology.  

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

Disclosure link: 
Committee Disclosures

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
 

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until November 27, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.